This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Print Page   |   Contact Us   |   Sign In   |   Register
Community Search
CMC Strategy Forum Europe 2020
Share |
 

 

CASSS 2020 COVID-19 Action Plan

Updated March 20, 2020
Due to the current situation with the COVID-19 (also known as coronavirus) outbreak, we will not be able to hold the CMC Strategy Forum Europe 2020 as planned. We are currently exploring alternatives, including virtual options, to deliver the great content that our community has come to expect from the Europe CMC Strategy Forum. We are incredibly grateful for your support and flexibility during this difficult time.  We will continue to keep you updated as new information becomes available.

Introduction
On behalf of the CMC Strategy Forum Global Steering Committee and CASSS, I would like to extend to you a warm welcome to the 14th meeting of the CMC Strategy Forum Europe that will be held 11-13 May 2020 in Stockholm, Sweden. 

The purpose of the CMC Strategy Forum Europe 2020 is to offer a blend of topics that characterize the challenges facing the biotechnology industry in the next decade. This Forum focuses on relevant CMC issues throughout the lifecycle of a product and thereby fosters collaborative technical and regulatory interactions. The Forum strives to share information with the regulatory agencies to assist them in merging good scientific and regulatory practices. The Forum will follow the established model of the CMC Forum series with focus on topics and regulatory updates relevant for Europe. The technical sessions will be: Challenges in Adeno Associated Virus (AAV) Manufacture; ICH Updates: Q12, Q13, Q14, Q5A; Medical Device: Challenges and Opportunities; NGS as a Replacement for Conventional Adventitious Agents Testing, including the in vivo Test; and Patient Focused Quality Standards for Large Molecules and Advanced Therapy Products. 

With this exciting program, I would like to extend to you an invitation to attend and participate actively in making this Forum a great success.

Wassim Nashabeh
On behalf of the CMC Strategy Forum Global Steering Committee

 

 


 

Want more information? Check out the "More in this Section" dropdown box at the top of the page! 
Or contact CASSS at 510-428-0740 or casss@casss.org


 

 

more Calendar

2/6/2020 » 4/30/2020
WCBP 2020 On-Demand

4/26/2020 » 4/28/2020
Bioassays 2020

5/11/2020 » 5/13/2020
CMC Strategy Forum Europe 2020

Featured Members
Membership Software Powered by YourMembership  ::  Legal